Press release
Asthma Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Domain | DelveInsight
Asthma Pipeline
Learn more about our innovative Asthma Pipeline today! @ https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash
Key Takeaways from the Asthma Pipeline Report
• In August 2026, Connect Biopharma initiated a Phase II Seabreeze STAT IV study evaluating intravenous rademikibart as an add-on treatment for acute asthma exacerbations in patients with type 2 inflammation. The company expects topline results from its Phase II asthma study in September 2026.
• DelveInsight's Asthma pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Asthma treatment.
• The leading Asthma Companies such as AstraZeneca, Enveda, Celldex Therapeutics, SinoMab BioScience Ltd, Anhui Palo Alto Pharmaceuticals, Inc., HUNAN MABGEEK BIOTECH CO., LTD, Chiesi Farmaceutici S.p.A., Arrowhead Pharmaceuticals, Akeso, Keymed Biosciences Co. Ltd, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Pfizer, Ethris GmbH, Windward Bio, Upstream Bio Inc., Jemincare, Longbio Pharma, Kymera Therapeutics, Inc., Avalo Therapeutics, Inc., Haisco Pharmaceutical Group Co., Ltd., Innovent Biologics (Suzhou) Co. Ltd., Sanofi, Amgen, Adovate, LLC and others.
• Promising Asthma Therapies such as HSK31858, Dexpramipexole Dihydrochloride, Benralizumab, Dupilumab, Rocatinlimab, Mepolizumab, and others.
Stay informed about the cutting-edge advancements in Asthma treatments @ https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash
The Asthma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Asthma Pipeline Report also highlights the unmet needs with respect to the Asthma.
Asthma Overview
Asthma is a prevalent chronic inflammatory respiratory condition affecting millions of people worldwide and presents substantial challenges in both diagnosis and management. This respiratory condition is characterized by inflammation of the airways, causing intermittent airflow obstruction and bronchial hyperresponsiveness. The prevalence and severity of asthma are determined by a complex interplay between genetic and environmental factors. Asthma symptoms vary between individuals and can sometimes worsen into episodes known as asthma attacks, often occurring at night or during physical activity. Common signs include a persistent cough (especially at night), wheezing during breathing, shortness of breath even at rest, and a feeling of chest tightness that makes deep breathing difficult. Symptoms may intensify with triggers such as colds, weather changes, dust, smoke, pollen, or strong odors. Since similar symptoms can arise from other conditions, it is important to consult a healthcare provider for proper evaluation and diagnosis.
Asthma Emerging Drugs Profile
• GB-0895: Generate:Biomedicines
GB-0895 is an investigational antibody that binds and neutralizes thymic stromal lymphopoietin (TSLP) to help reduce downstream inflammatory signaling in severe asthma. Thymic stromal lymphopoietin (TSLP) is an epithelial cytokine that helps drive airway inflammation and asthma exacerbations. It is engineered for an extended half-life and is being studied for twice-yearly subcutaneous dosing, which may offer administration flexibility and convenience if proven safe and effective. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Asthma.
• AZD-4604: AstraZeneca
AZD4604 is a potent and selective inhibitor of Janus kinase family member, JAK1, intended for inhaled add-on treatment of moderate to severe asthma, uncontrolled on standard of care. Due to the broad anti-inflammatory properties of JAK1 inhibition, AZD4604 is predicted to provide benefit to steroid sensitive and insensitive asthma endotypes, thereby offering a differentiation opportunity from existing biologics. In a preclinical ovalbumin-challenge rat model of allergic asthma, lung and systemic delivered AZD4604 showed reduction of pSTAT3 and pSTAT5, indicating target engagement in the lung. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Asthma.
• ENV-294: Enveda
ENV-294 is a novel, first-in-class, small molecule discovered using Enveda's proprietary platform for the treatment of multiple inflammatory conditions. It targets a novel non-kinase inflammatory pathway distinct from current advanced therapies like JAK-STAT or cytokine signaling, aiming to deliver an oral agent with high efficacy and favorable safety. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Asthma.
• CDX-622: Celldex Therapeutics
CDX-622 is a bispecific antibody that targets two complementary, clinically validated pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin (TSLP) and depleting mast cells via stem cell factor (SCF) starvation. SCF activation of the KIT receptor is required for mast cell survival and plays a key role in their activation, maturation and tissue recruitment. Combined neutralization of SCF and TSLP with CDX-622 is expected to simultaneously reduce tissue mast cells and inhibit Type 2 inflammatory responses to potentially offer enhanced therapeutic benefit in inflammatory and fibrotic disorders. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Asthma.
• SM17: SinoMab BioScience Ltd
SM17 is a novel, first-in-class humanized IgG4-κ monoclonal anƟbody designed to modulate Type II inflammatory responses by targeƟng the receptor of interleukin 25 (IL-25), an "alarmin" molecule central to Type 2 immunity. By binding to the IL-25 receptor (IL-17RB) on Type 2 innate lymphoid cells (ILC2s) and Th2 cells, SM17 blocks IL-25-induced signaling cascades and suppresses downstream cytokines including IL-4, IL-5, and IL-13. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Asthma.
Learn more about Asthma Drugs opportunities in our groundbreaking Asthma Research and development projects @ https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash
The Asthma Pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Asthma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Asthma Treatment.
• Asthma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Asthma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Asthma market.
Asthma Companies
AstraZeneca, Enveda, Celldex Therapeutics, SinoMab BioScience Ltd, Anhui Palo Alto Pharmaceuticals, Inc., HUNAN MABGEEK BIOTECH CO., LTD, Chiesi Farmaceutici S.p.A., Arrowhead Pharmaceuticals, Akeso, Keymed Biosciences Co. Ltd, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Pfizer, Ethris GmbH, Windward Bio, Upstream Bio Inc., Jemincare, Longbio Pharma, Kymera Therapeutics, Inc., Avalo Therapeutics, Inc., Haisco Pharmaceutical Group Co., Ltd., Innovent Biologics (Suzhou) Co. Ltd., Sanofi, Amgen, Adovate, LLC and others.
Asthma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Asthma Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Discover the latest advancements in Asthma treatment by visiting our website @ https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash
Scope of the Asthma Pipeline Report
• Coverage- Global
• Asthma Companies- AstraZeneca, Enveda, Celldex Therapeutics, SinoMab BioScience Ltd, Anhui Palo Alto Pharmaceuticals, Inc., HUNAN MABGEEK BIOTECH CO., LTD, Chiesi Farmaceutici S.p.A., Arrowhead Pharmaceuticals, Akeso, Keymed Biosciences Co. Ltd, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Pfizer, Ethris GmbH, Windward Bio, Upstream Bio Inc., Jemincare, Longbio Pharma, Kymera Therapeutics, Inc., Avalo Therapeutics, Inc., Haisco Pharmaceutical Group Co., Ltd., Innovent Biologics (Suzhou) Co. Ltd., Sanofi, Amgen, Adovate, LLC and others.
• Asthma Therapies- HSK31858, Dexpramipexole Dihydrochloride, Benralizumab, Dupilumab, Rocatinlimab, Mepolizumab, and others.
• Asthma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Asthma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Read the full details of Asthma Pipeline on our website @ https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash
Table of Content
1. Introduction
2. Executive Summary
3. Asthma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Asthma - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Mid Stage Products (Phase II)
9. Early Stage Products (Phase I)
10. Preclinical and Discovery Stage Products
11. Inactive Products
12. Asthma - Key Companies
13. Asthma - Key Products
14. Asthma - Unmet Needs
15. Asthma - Market Drivers and Barriers
16. Asthma - Future Perspectives and Conclusion
17. Asthma - Analyst Views
18. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Asthma Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Domain | DelveInsight here
News-ID: 4611473 • Views: …
More Releases from DelveInsight Business Research LLP
Huntington's Disease Market: Steady Growth Ahead as Gene-Silencing and RNA-Targe …
DelveInsight's "Huntington's Disease Market Insights, Epidemiology, and Market Forecast-2036" report offers an in-depth understanding of Huntington's disease, historical and forecasted epidemiology, as well as Huntington's Disease market trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
To know more about the Huntington's Disease market outlook, drug uptake, treatment scenario, and epidemiology trends, visit: https://www.delveinsight.com/sample-request/huntingtons-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Key Highlights from the Huntington's Disease Market Report
• The Huntington's Disease…
Necrotizing Enterocolitis Market: Steep Growth Ahead as Pipeline Advances Toward …
DelveInsight's "Necrotizing Enterocolitis Market Insights, Epidemiology, and Market Forecast-2036" report offers an in-depth understanding of Necrotizing Enterocolitis (NEC), historical and forecasted epidemiology, as well as market trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
To know more about the Necrotizing Enterocolitis market outlook, drug uptake, treatment scenario, and epidemiology trends, visit: https://www.delveinsight.com/sample-request/necrotizing-enterocolitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Key Highlights from the Necrotizing Enterocolitis Market Report
• The Necrotizing Enterocolitis market…
Adrenocortical Carcinoma Market: Steady Growth Driven by Emerging Pipeline Innov …
DelveInsight's "Adrenocortical Carcinoma Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of Adrenocortical Carcinoma (ACC), historical and forecasted epidemiology as well as the ACC market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
To Know in detail about the Adrenocortical Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Adrenocortical Carcinoma Market Forecast https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Key Highlights from Adrenocortical…
The Global Plaque Modification Devices Market Size is projected to grow at a CAG …
The Plaque Modification Devices market is estimated at USD 3,622.27 million in 2025 and is projected to reach USD 6,725.92 million by 2034. Growth is anchored in the rising prevalence of atherosclerosis and calcified CAD/PAD, the shift toward minimally invasive endovascular procedures, and continuous product innovation.
DelveInsight's Plaque Modification Devices Market Insights Report 2034 provides the current and forecast market analysis, individual leading Plaque Modification Devices companies' market shares, challenges, Plaque…
More Releases for Asthma
Anti Asthma Drugs Market Growth Trajectory: Enhancing Global Asthma Care Outcome …
The global Anti Asthma Drugs Market continues to demonstrate steady growth as healthcare providers increasingly prioritize long-term disease management and improved patient outcomes. Asthma remains one of the most prevalent chronic respiratory conditions worldwide, creating sustained demand for effective therapeutic interventions. The market is benefiting from rising diagnosis rates, greater awareness of respiratory health, and expanding access to healthcare services across both developed and emerging economies.
According to Verified Market Research®,…
Evolving Market Trends In The Asthma Spacers Industry: Smart Inhaler Devices Rev …
The Asthma Spacers Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Asthma Spacers Market Size During the Forecast Period?
The asthma spacers market has grown steadily, forecasted to rise from $1.88 billion in 2024 to $2.01 billion in 2025 at a CAGR…
Asthma Relief Reimagined: Trends Driving Asthma Spacer Innovation
The Business Research Company recently released a comprehensive report on the Global Asthma Spacers Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free…
Asthma Warning Sensors Market Connected Care for Asthma: How Warning Sensors Imp …
Asthma Warning Sensors Market Market to Record an Exponential CAGR by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Asthma Warning Sensors Market Size, Share & Trends Analysis Report By Type (Wearable v/s Non-Wearable), By Technology (AI, IoT, Machine Learning, Others), By Parameter Measured (FEV1 v/s Peak Flow), By End User (Hospitals & Clinics v/s Homecare)- Market…
Asthma Spacers Market Optimizing Asthma Treatment: How Spacers are Improving Del …
Asthma Spacers Market Assessment worth $ 2.47 Billion by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Asthma Spacers Market- by Product (Space Chamber Plus, A2A Spacer, Flo-Tone CR, Able Spacer, AeroChamber, Volumatic, Vortex, OptiChamber), Application (Hospital Pharmacies, Online Pharmacies and Retail Pharmacies), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
Get a free sample copy of…
Severe Asthma Treatment Market - Revitalizing Quality of Life: Severe Asthma Tre …
Newark, New Castle, USA: The "Severe Asthma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Severe Asthma Treatment Market: https://www.growthplusreports.com/report/severe-asthma-treatment-market/8939
This latest report researches the industry structure,…
